Risk of Hospitalization for Severe Hypersensitivity (including Severe Skin Reactions) in Patients with Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
Study identifier:CV181-103
ClinicalTrials.gov identifier:NCT01086319
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Comparison of Risk of Hospitalization for Severe Hypersensitivity (including Severe Cutaneous Reactions) Between Patients with Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments
Medical condition
Diabetes Mellitus, Type 2
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
113505
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Aug 2009
Primary Completion Date: 01 Dec 2015
Study Completion Date: 01 Dec 2015
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Sept 2016 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Bristol Myers Squibb, University of Pennsylvania
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Patients exposed to saxagliptin | - |
| Patients exposed to oral antidiabetic drugs (not saxagliptin) | - |
Contacts
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
